AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,227.00GBp
8:34am EDT
Change (% chg)

110.00p (+2.67%)
Prev Close
4,117.00p
Open
4,169.50p
Day's High
4,236.00p
Day's Low
4,161.50p
Volume
1,119,821
Avg. Vol
2,467,874
52-wk High
4,931.68p
52-wk Low
3,746.00p

AZN.L

Chart for AZN.L

About

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for Cardiovascular and Metabolic diseases; Oncology; Respiratory, Inflammation and Autoimmunity, Infection, Neuroscience and Gastrointestinal. The Company's medicines include Crestor for... (more)

Overall

Beta: 0.60
Market Cap(Mil.): £52,040.48
Shares Outstanding(Mil.): 1,263.79
Dividend: 57.50
Yield (%): 4.43

Financials

  AZN.L Industry Sector
P/E (TTM): 67.57 35.51 35.63
EPS (TTM): 0.61 -- --
ROI: 2.91 15.46 14.92
ROE: 5.85 16.02 15.77
Search Stocks

BRIEF-AstraZeneca enters license agreement with Daiichi Sankyo

* AstraZeneca enters license agreement with Daiichi Sankyo for development and commercialisation of Flumist in Japan

02 Sep 2015

Valeant picks up AstraZeneca psoriasis drug after Amgen exit

- Canada's Valeant Pharmaceuticals International Inc is buying rights to AstraZeneca Plc's late-stage experimental psoriasis drug brodalumab after it was dropped by Amgen Inc in May.

01 Sep 2015

UPDATE 1-Valeant picks up AstraZeneca psoriasis drug after Amgen exit

Sept 1 - Canada's Valeant Pharmaceuticals International Inc is buying rights to AstraZeneca Plc's late-stage experimental psoriasis drug brodalumab after it was dropped by Amgen Inc in May.

01 Sep 2015

Valeant gets right to develop AstraZeneca's psoriasis drug

Sept 1 - Canada's Valeant Pharmaceuticals International Inc said it has been granted an exclusive license by AstraZeneca Plc to develop and commercialize its late-stage experimental psoriasis drug brodalumab.

01 Sep 2015

AstraZeneca names Genentech's Bohen as chief medical officer

LONDON - British pharmaceutical company AstraZeneca named Sean Bohen as its chief medical officer, in an appointment that it said could help accelerate the development of new oncology and immunology medicines.

24 Aug 2015

AstraZeneca names Genentech's Bohen as chief medical officer

LONDON, Aug 24 - British pharmaceutical company AstraZeneca named Sean Bohen as its chief medical officer, in an appointment that it said could help accelerate the development of new oncology and immunology medicines.

24 Aug 2015

BRIEF-Astrazeneca and Peregrine Pharma to collaborate on immuno-oncology combination clinical trial

* Astrazeneca and Peregrine Pharmaceuticals to collaborate on immuno-oncology combination clinical trial

24 Aug 2015

BRIEF-Astrazeneca appoints Sean Bohen as chief medical officer

* Appoints Dr Sean Bohen as executive vice president of global medicines development and chief medical officer Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)

24 Aug 2015

Deals of the day- Mergers and acquisitions

Aug 10 - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:

10 Aug 2015

AstraZeneca bags another cancer drug deal, this time with Inovio

LONDON - AstraZeneca has clinched its third deal in less than a week to bolster its strategically important cancer drug pipeline by signing up rights to an experimental immune system-boosting medicine from Inovio Pharmaceuticals.

10 Aug 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks